The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) hit a new 52-week high and has $47.08 target or 32.00% above today’s $35.67 share price. The 6 months bullish chart indicates low risk for the $728.14M company. The 1-year high was reported on Oct, 3 by Barchart.com. If the $47.08 price target is reached, the company will be worth $233.00 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 487,704 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 596.17% since February 29, 2016 and is uptrending. It has outperformed by 583.95% the S&P500.
Analysts await CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) to report earnings on November, 8. They expect $-0.97 EPS, down 64.41% or $0.38 from last year’s $-0.59 per share. After $-1.06 actual EPS reported by CoLucid Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage
Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. CoLucid Pharmaceuticals has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Zacks upgraded the shares of CLCD in a report on Thursday, September 3 to “Hold” rating. The stock has “Buy” rating given by Stifel Nicolaus on Monday, September 19. The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) earned “Buy” rating by William Blair on Friday, August 14.
According to Zacks Investment Research, “CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company’s product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.”
Another recent and important CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) news was published by Fool.com which published an article titled: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday” on September 15, 2016.
CLCD Company Profile
CoLucid Pharmaceuticals, Inc., incorporated on August 31, 2005, is a Phase III clinical-stage biopharmaceutical company. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.